311 related articles for article (PubMed ID: 31533639)
1. Rapid development of HIV elite control in a patient with acute infection.
Morley D; Lambert JS; Hogan LE; De Gascun C; Redmond N; Rutishauser RL; Thanh C; Gibson EA; Hobbs K; Bakkour S; Busch MP; Farrell J; McGetrick P; Henrich TJ
BMC Infect Dis; 2019 Sep; 19(1):815. PubMed ID: 31533639
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
[TBL] [Abstract][Full Text] [Related]
3. Immune Activation and HIV-Specific CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers.
Ganesh A; Lemongello D; Lee E; Peterson J; McLaughlin BE; Ferre AL; Gillespie GM; Fuchs D; Deeks SG; Hunt PW; Price RW; Spudich SS; Shacklett BL
AIDS Res Hum Retroviruses; 2016 Aug; 32(8):791-800. PubMed ID: 27019338
[TBL] [Abstract][Full Text] [Related]
4. Evidence for innate immune system activation in HIV type 1-infected elite controllers.
Krishnan S; Wilson EM; Sheikh V; Rupert A; Mendoza D; Yang J; Lempicki R; Migueles SA; Sereti I
J Infect Dis; 2014 Mar; 209(6):931-9. PubMed ID: 24185941
[TBL] [Abstract][Full Text] [Related]
5. Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1.
Bello G; Velasco-de-Castro CA; Bongertz V; Rodrigues CA; Giacoia-Gripp CB; Pilotto JH; Grinsztejn B; Veloso VG; Morgado MG
J Med Virol; 2009 Oct; 81(10):1681-90. PubMed ID: 19697415
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.
Henrich TJ; Hatano H; Bacon O; Hogan LE; Rutishauser R; Hill A; Kearney MF; Anderson EM; Buchbinder SP; Cohen SE; Abdel-Mohsen M; Pohlmeyer CW; Fromentin R; Hoh R; Liu AY; McCune JM; Spindler J; Metcalf-Pate K; Hobbs KS; Thanh C; Gibson EA; Kuritzkes DR; Siliciano RF; Price RW; Richman DD; Chomont N; Siliciano JD; Mellors JW; Yukl SA; Blankson JN; Liegler T; Deeks SG
PLoS Med; 2017 Nov; 14(11):e1002417. PubMed ID: 29112956
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers.
Rosás-Umbert M; Llano A; Bellido R; Olvera A; Ruiz-Riol M; Rocafort M; Fernández MA; Cobarsi P; Crespo M; Dorrell L; Del Romero J; Alcami J; Paredes R; Brander C; Mothe B
J Virol; 2019 Feb; 93(4):. PubMed ID: 30487276
[TBL] [Abstract][Full Text] [Related]
8. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children.
Ananworanich J; Puthanakit T; Suntarattiwong P; Chokephaibulkit K; Kerr SJ; Fromentin R; Bakeman W; Intasan J; Mahanontharit A; Sirivichayakul S; Chomont N;
AIDS; 2014 Apr; 28(7):1015-20. PubMed ID: 24384692
[TBL] [Abstract][Full Text] [Related]
9. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.
Alatrakchi N; Duvivier C; Costagliola D; Samri A; Marcelin AG; Kamkamidze G; Astriti M; Agher R; Calvez V; Autran B; Katlama C
AIDS; 2005 Jan; 19(1):25-33. PubMed ID: 15627030
[TBL] [Abstract][Full Text] [Related]
10. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy.
Hatano H; Delwart EL; Norris PJ; Lee TH; Dunn-Williams J; Hunt PW; Hoh R; Stramer SL; Linnen JM; McCune JM; Martin JN; Busch MP; Deeks SG
J Virol; 2009 Jan; 83(1):329-35. PubMed ID: 18945778
[TBL] [Abstract][Full Text] [Related]
11. Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy.
Jilg N; Garcia-Broncano P; Peluso M; Segal FP; Bosch RJ; Roberts-Toler C; Chen SMY; Van Dam CN; Keefer MC; Kuritzkes DR; Landay AL; Deeks S; Yu XG; Sax PE; Li JZ;
J Infect Dis; 2020 Nov; 222(11):1837-1842. PubMed ID: 32496516
[TBL] [Abstract][Full Text] [Related]
12. Case report: mechanisms of HIV elite control in two African women.
Moosa Y; Tanko RF; Ramsuran V; Singh R; Madzivhandila M; Yende-Zuma N; Abrahams MR; Selhorst P; Gounder K; Moore PL; Williamson C; Abdool Karim SS; Garrett NJ; Burgers WA
BMC Infect Dis; 2018 Jan; 18(1):54. PubMed ID: 29370775
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size.
Jain V; Hartogensis W; Bacchetti P; Hunt PW; Hatano H; Sinclair E; Epling L; Lee TH; Busch MP; McCune JM; Pilcher CD; Hecht FM; Deeks SG
J Infect Dis; 2013 Oct; 208(8):1202-11. PubMed ID: 23852127
[TBL] [Abstract][Full Text] [Related]
14. Residual HIV-specific CD4 and CD8 T cell frequencies after prolonged antiretroviral therapy reflect pretreatment plasma virus load.
Oxenius A; Price DA; Dawson SJ; Günthard HF; Fischer M; Perrin L; Ramirez E; Fagard C; Hirschel B; Scullard G; Weber JN; McLean AR; Phillips RE;
AIDS; 2002 Nov; 16(17):2317-22. PubMed ID: 12441804
[TBL] [Abstract][Full Text] [Related]
15. A case report of HIV-1 superinfection in an HIV controller leading to loss of viremia control: a retrospective of 10 years of follow-up.
Caetano DG; Côrtes FH; Bello G; de Azevedo SSD; Hoagland B; Villela LM; Grinsztejn B; Veloso VG; Guimarães ML; Morgado MG
BMC Infect Dis; 2019 Jul; 19(1):588. PubMed ID: 31277590
[TBL] [Abstract][Full Text] [Related]
16. Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapy.
Zheng L; Taiwo B; Gandhi RT; Hunt PW; Collier AC; Flexner C; Bosch RJ
J Acquir Immune Defic Syndr; 2014 Oct; 67(2):153-60. PubMed ID: 25072610
[TBL] [Abstract][Full Text] [Related]
17. Single-copy assay quantification of HIV-1 RNA in paired cerebrospinal fluid and plasma samples from elite controllers.
Dahl V; Peterson J; Spudich S; Lee E; Shacklett BL; Price RW; Palmer S
AIDS; 2013 Apr; 27(7):1145-9. PubMed ID: 23211774
[TBL] [Abstract][Full Text] [Related]
18. CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy.
Boulassel MR; Chomont N; Pai NP; Gilmore N; Sékaly RP; Routy JP
J Clin Virol; 2012 Jan; 53(1):29-32. PubMed ID: 22019250
[TBL] [Abstract][Full Text] [Related]
19. A higher CD4/CD8 ratio correlates with an ultralow cell-associated HIV-1 DNA level in chronically infected patients on antiretroviral therapy: a case control study.
Yue Y; Wang N; Han Y; Zhu T; Xie J; Qiu Z; Song X; Li Y; Routy JP; Wang J; Li T
BMC Infect Dis; 2017 Dec; 17(1):771. PubMed ID: 29246197
[TBL] [Abstract][Full Text] [Related]
20. Absence of detectable HIV-1 viremia after treatment cessation in an infant.
Persaud D; Gay H; Ziemniak C; Chen YH; Piatak M; Chun TW; Strain M; Richman D; Luzuriaga K
N Engl J Med; 2013 Nov; 369(19):1828-35. PubMed ID: 24152233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
